Its derivative SNIPER(ABL)-39 with dasatinib and LCL161 for IAP recruitment was found to have more potent BCR-ABL degradation activity and showed high activities against proliferation of several CML cells with EC50 values of ~ 8 nM [57, 73]. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.